Acute Renal Failure (ARF) Market Report 2026

The acute renal failure (arf) market size has grown strongly in recent years. It will grow from $6.6 billion in 2025 to $7.14 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to rising prevalence of hypertension and diabetes, increasing hospital-based renal care, limited awareness of early arf symptoms, adoption of conventional dialysis methods, growth in hospital infrastructure.

The acute renal failure (arf) market size is expected to see strong growth in the next few years. It will grow to $9.71 billion in 2030 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to development of novel nephroprotective drugs, integration of ai-based diagnostics, expansion of home healthcare services, increasing geriatric population, rising investment in renal disease research. Major trends in the forecast period include rising adoption of advanced dialysis and renal support therapies, increasing focus on early diagnosis of acute kidney injury, growth in use of nephroprotective drug therapies, expansion of imaging and biopsy-based diagnostic techniques, increasing preference for home healthcare management for arf patients.

The increasing prevalence of chronic kidney diseases is expected to drive the growth of the acute renal failure (ARF) market going forward. Chronic kidney disease (CKD) is a long-term condition in which the kidneys are damaged and unable to filter blood effectively. The rising prevalence of CKD is attributed to increasing rates of diabetes, hypertension, obesity, aging populations, and lifestyle-related factors worldwide. Acute renal failure, defined by the sudden loss of kidney function, can act as a key trigger or aggravating factor for chronic kidney disease by causing lasting damage to kidney tissues, reducing filtration efficiency, and increasing the risk of progressive, long-term kidney dysfunction if not managed properly. For instance, in June 2023, according to a report by Kidney Research UK, a UK-based non-profit organization, approximately 7.2 million people in the UK are living with chronic kidney disease, representing over 10% of the population. Of these, 3.25 million are in advanced stages, while another 3.9 million are in early stages. By 2033, the number of individuals affected by CKD is projected to rise to 7.61 million. Therefore, the increasing prevalence of chronic kidney diseases is driving growth in the acute renal failure (ARF) market.

Major companies operating in the acute renal failure (ARF) market are focusing on obtaining regulatory approvals for drugs to expand their reach and strengthen their position in treating severe acute kidney injury (AKI). Regulatory approvals involve formal authorization from governmental or regulatory bodies to allow the marketing and public use of drugs, medical devices, or treatments. For instance, in February 2024, CalciMedica, a US-based clinical-stage biopharmaceutical company, received FDA approval for an IND application to initiate a Phase 2 trial of Auxora to evaluate its efficacy in treating severe acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF), a condition with high mortality rates. The KOURAGE trial is a randomized, double-blind, placebo-controlled study designed to enroll approximately 150 patients with Stage 2 and 3 AKI who also have AHRF, assessing the efficacy of Auxora over five daily doses by measuring the number of days patients remain alive without the need for ventilators or dialysis up to 30 days post-treatment.

In June 2023, Elicio Therapeutics Inc., a US-based biotechnology company, completed a merger with Angion Biomedica Corp. to expand its immunotherapy pipeline. Through this merger, Elicio Therapeutics aims to strengthen its immunotherapy portfolio by leveraging Angion Biomedica’s expertise and resources, enhancing the development of innovative treatments for various diseases, and accelerating progress for novel therapies in the biotechnology sector. Angion Biomedica is a US-based biopharmaceutical company specializing in the development of treatments for acute renal failure (ARF).

Major companies operating in the acute renal failure (arf) market are Pfizer Inc, Novartis AG, Baxter International Inc, Fresenius Medical Care AG and Co KGaA, Medtronic plc, Asahi Kasei Corporation, Astellas Pharma Inc, NIKKISO Co Ltd, NIPRO Corporation, Quark Pharmaceuticals Inc, AM Pharma BV, Sentien Biotechnologies, Angion Biomedica Corp, Alloksys Life Sciences BV, Theravance Biopharma, Kissei Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd, B Braun Melsungen AG, Chiesi Farmaceutici SpA, Takeda Pharmaceutical Company Limited.

North America was the largest region in the acute renal failure (ARF) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute renal failure (arf) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acute renal failure (arf) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the acute renal failure market by increasing costs of imported dialysis equipment, imaging devices, and specialty drugs. Segments such as intravenous drug therapies, dialysis systems, and advanced diagnostic tools are most affected, with north america, europe, and asia-pacific regions facing higher procurement costs. This has resulted in increased treatment expenses and supply chain delays. On the positive side, tariffs are encouraging local manufacturing of renal care devices and domestic production of critical therapeutics, enhancing long-term market resilience.

The acute renal failure (arf) market research report is one of a series of new reports that provides acute renal failure (arf) market statistics, including acute renal failure (arf) industry global market size, regional shares, competitors with a acute renal failure (arf) market share, detailed acute renal failure (arf) market segments, market trends and opportunities, and any further data you may need to thrive in the acute renal failure (arf) industry. This acute renal failure (arf) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Acute renal failure (ARF), also known as acute kidney injury (AKI), is a sudden and rapid decline in kidney function occurring over hours or days. It is managed through various approaches, including medication, fluid management, and dialysis, to restore kidney function and prevent further complications.

The main types of acute renal failure (ARF) are prerenal acute renal failure, renal acute renal failure, and postrenal acute renal failure. Prerenal acute renal failure arises from factors affecting blood flow to the kidneys, such as dehydration or heart failure. Drug treatments include diuretics, vasopressors, erythropoiesis-stimulating agents (ESAs), phosphate binders, calcium and vitamin D supplements, antibiotics, and other medications. These are administered via routes such as oral and intravenous. Diagnostic methods include computed tomography (CT) scans, kidney biopsies, and ultrasounds, and treatments are provided by various end users, including clinics, hospitals, home healthcare, and others.

The acute renal failure (ARF) market consists of revenues earned by entities by providing services such as dialysis treatment, emergency care, renal replacement therapies, post-acute care for kidney recovery, and hospital-based interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute renal failure (ARF) market also includes sales of dialysis equipment, normal saline, urine test kits, and urinary catheters. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.